Sorafenib, an oncogenic kinase inhibitor, is currently the sole treatment with demonstrated efficacy in liver cancer. In this issue, Galmiche and coworkers report that the proapoptotic protein BAD, a member of the BCL2 family, is a determinant of the cytotoxic effect of sorafenib on liver cancer cells. ABT-737, an inhibitor of proteins of the BCL2 family with a BAD-like reactivity, sensitizes liver cancer cells to the cytotoxic effect of sorafenib. For further details, please see Galmiche and colleagues on page 1116 in this issue.